The European Medicines Agency granted orphan drug designation to Achillion Pharmaceuticals Inc. (Nasdaq: ACHN) for its ACH-4471 to treat C3 glomerulopathy lifting the stock price 45 cents to close at $3.41.
Orphan drug granted to Achillion Pharmaceuticals
February 26, 2018 at 16:11 PM EST
